BioInvest.com is the web portal of the Medical Technology Stock Letter. In addition to providing convenient access to the Letter, this site includes in-depth research and analysis of a unique portfolio of bio-pharmaceutical companies and our insights regarding relevant trends in the biotechnology industry.
BioInvest.com helps individual and professional investors stay ahead of the curve with timely information about market-moving events and by offering comprehensive analysis of company and industry catalysts. When appropriate, we also guide our readers to other websites such as ClinicalTrials.gov to gain a complete understanding of the medicines and technologies being developed by the companies we follow.
From time to time, independent contributors will provide added value for our subscribers to gain additional viewpoints on relevant topics (e.g., whitepapers) of interest for the current and future biotechnology industry.
John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000.
John McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy.
At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities.His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.